Home > News > Altair Nanotechnologies Signs Agreement With Lilly
May 2nd, 2006
Altair Nanotechnologies Signs Agreement With Lilly
Abstract:
Altair Nanotechnologies Inc. (NASDAQ: ALTI) announced today it has entered into a Collaborative Research, License and Commercialization Agreement with the Elanco Animal Health Division of Eli Lilly and Company. The agreement provides Elanco with exclusive rights to develop animal health products using Altairnano's nanotechnology-based products.
Source:
marketwire
Bookmark:
Nanomedicine
Nanoparticle Harnesses Powerful Radiation Therapy for Cancer May 20th, 2013
Microneedle-Delivered Nanoparticles Boost Antitumor Vaccines May 20th, 2013
New Nanopore Sensor Simplifies Analysis of Methylated DNA May 20th, 2013
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013
Announcements
Competition in the Quantum World May 20th, 2013
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013
Penn engineers' nanoantennas improve infrared sensing May 20th, 2013
Researchers Perform Fastest Measurements Ever Made of Ion Channel Proteins May 20th, 2013